Overview
Compare with Tivity Health, Sotera Health Co or Progyny, Inc., or pick any stock.
- TickerVMD on Nasdaq1
- IndustryServices-Misc Health & Allied Services, NEC1
- HeadquartersLafayette, Louisiana1
- Incorporated inBritish Columbia, Canada2
- Business address625 E. Kaliste Saloom Rd., Lafayette, La 705082
- Filer categoryAccelerated filer2
See how the biggest companies compare on our leaderboards
Viemed Healthcare, Inc. (the "Company" or "Viemed"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. The Company’s primary service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
57.5%Gross margin5
8.5%Operating margin5
5.5%Net margin5
20.5%Revenue growth, 20255
10.6%Return on equity5
0.08×Debt to equity5
$11.9MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Equipment Sales brought in 67% of the revenue VIEMED HEALTHCARE, INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Equipment Sales | $25.8M | $30.9M | $50.3M |
| Service | $10.7M | $20.1M | $24.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue42¢$114.8M
- Research and development1¢$3.0M
- Selling, general and admin45¢$121.4M
- Other costs4¢$9.8M
- Income tax2¢$6.4M
- Profit6¢$14.9M
Out of $270.3M in revenue.5
Where each dollar of operating cash went, fiscal 2025
- Capital spending75¢$40.0M
- Share buybacks25¢$13.2M
Out of $51.9M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $270.3M | $224.3M | $183.0M |
| Cost of revenue | $114.8M | $91.1M | $70.2M |
| Gross profit | $155.5M | $133.2M | $112.8M |
| Selling, general and administrative | $121.4M | $106.2M | $87.9M |
| Research and development | $3.0M | $3.1M | $2.8M |
| Stock-based compensation | $9.1M | $6.3M | $5.8M |
| Depreciation and amortization | $1.5M | $1.5M | $1.4M |
| Loss (gain) on disposal of property and equipment | -$2.2M | -$1.9M | $645.0K |
| Other expense (income), net | -$252.0K | $173.0K | -$98.0K |
| Income from operations | $22.9M | $17.9M | $14.3M |
| Income (loss) from investments | $0 | -$954.0K | $485.0K |
| Interest expense, net | -$1.2M | -$776.0K | -$424.0K |
| Net income before taxes | $21.8M | $16.2M | $14.4M |
| Provision for income taxes | $6.4M | $4.8M | $4.1M |
| Net income | $15.4M | $11.4M | $10.2M |
| Net income attributable to noncontrolling interest | $442.0K | $144.0K | $0 |
| Net income attributable to Viemed Healthcare, Inc. | $14.9M | $11.3M | $10.2M |
| Basic (in USD per share) | $0.38 | $0.29 | $0.27 |
| Diluted (in USD per share) | $0.37 | $0.28 | $0.25 |
| Basic (in shares) | 38.9M shares | 38.8M shares | 38.4M shares |
| Diluted (in shares) | 40.8M shares | 40.8M shares | 40.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $13.5M | $17.5M | ||
| Accounts receivable, net | $25.6M | $24.9M | ||
| Inventory | $5.0M | $4.3M | ||
| Income tax receivable | $227.0K | $0 | ||
| Prepaid expenses and other assets | $4.1M | $6.1M | ||
| Total current assets | $48.5M | $52.9M | ||
| Property and equipment, net | $78.8M | $76.3M | ||
| Finance lease right-of-use assets | $0 | $50.0K | ||
| Operating lease right-of-use assets | $3.6M | $2.8M | ||
| Equity investments | $2.8M | $2.8M | ||
| Deferred tax asset | $5.3M | $8.4M | ||
| Identifiable intangibles, net | $1.3M | $848.0K | ||
| Goodwill | $58.9M | $33.0M | ||
| Total long-term assets | $150.7M | $124.2M | ||
| TOTAL ASSETS | $199.2M | $177.1M | ||
| Trade payables | $7.3M | $5.3M | ||
| Deferred revenue | $7.5M | $6.7M | ||
| Income taxes payable | $0 | $3.9M | ||
| Accrued liabilities | $23.9M | $20.2M | ||
| Finance lease liabilities, current portion | $0 | $50.0K | ||
| Operating lease liabilities, current portion | $1.2M | $811.0K | ||
| Current portion of long-term debt | $1.1M | $409.0K | ||
| Total current liabilities | $41.1M | $37.3M | ||
| Accrued liabilities | $922.0K | $846.0K | ||
| Operating lease liabilities, less current portion | $2.4M | $2.0M | ||
| Long-term debt | $11.3M | $3.6M | ||
| Total long-term liabilities | $14.6M | $6.4M | ||
| TOTAL LIABILITIES | $55.6M | $43.8M | ||
| Commitments and Contingencies | $0 | $0 | ||
| Common stock - No par value: unlimited authorized; 38,019,082 and 39,132,897 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $16.9M | $23.4M | ||
| Additional paid-in capital | $21.7M | $18.3M | ||
| Retained earnings | $102.9M | $89.7M | ||
| TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY | $141.5M | $131.4M | ||
| Noncontrolling interest in subsidiary | $2.0M | $1.9M | ||
| TOTAL SHAREHOLDERS' EQUITY | $143.5M | $133.3M | $113.9M | $97.1M |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $199.2M | $177.1M | ||
| Shares issued (in shares) | 38.0M shares | 39.1M shares | ||
| Outstanding (in shares) | 38.0M shares | 39.1M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $13.5M | $17.5M | ||
| Accounts receivable, net | $25.6M | $24.9M | ||
| Inventory | $5.0M | $4.3M | ||
| Income tax receivable | $227.0K | $0 | ||
| Prepaid expenses and other assets | $4.1M | $6.1M | ||
| Total current assets | $48.5M | $52.9M | ||
| Property and equipment, net | $78.8M | $76.3M | ||
| Finance lease right-of-use assets | $0 | $50.0K | ||
| Operating lease right-of-use assets | $3.6M | $2.8M | ||
| Equity investments | $2.8M | $2.8M | ||
| Deferred tax asset | $5.3M | $8.4M | ||
| Identifiable intangibles, net | $1.3M | $848.0K | ||
| Goodwill | $58.9M | $33.0M | ||
| Total long-term assets | $150.7M | $124.2M | ||
| TOTAL ASSETS | $199.2M | $177.1M | ||
| Trade payables | $7.3M | $5.3M | ||
| Deferred revenue | $7.5M | $6.7M | ||
| Income taxes payable | $0 | $3.9M | ||
| Accrued liabilities | $23.9M | $20.2M | ||
| Finance lease liabilities, current portion | $0 | $50.0K | ||
| Operating lease liabilities, current portion | $1.2M | $811.0K | ||
| Current portion of long-term debt | $1.1M | $409.0K | ||
| Total current liabilities | $41.1M | $37.3M | ||
| Accrued liabilities | $922.0K | $846.0K | ||
| Operating lease liabilities, less current portion | $2.4M | $2.0M | ||
| Long-term debt | $11.3M | $3.6M | ||
| Total long-term liabilities | $14.6M | $6.4M | ||
| TOTAL LIABILITIES | $55.6M | $43.8M | ||
| Commitments and Contingencies | $0 | $0 | ||
| Common stock - No par value: unlimited authorized; 38,019,082 and 39,132,897 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $16.9M | $23.4M | ||
| Additional paid-in capital | $21.7M | $18.3M | ||
| Retained earnings | $102.9M | $89.7M | ||
| TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY | $141.5M | $131.4M | ||
| Noncontrolling interest in subsidiary | $2.0M | $1.9M | ||
| TOTAL SHAREHOLDERS' EQUITY | $143.5M | $133.3M | $113.9M | $97.1M |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $199.2M | $177.1M | ||
| Shares issued (in shares) | 38.0M shares | 39.1M shares | ||
| Outstanding (in shares) | 38.0M shares | 39.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $15.4M | $11.4M | $10.2M |
| Depreciation and amortization | $28.6M | $25.4M | $21.9M |
| Stock-based compensation expense | $9.1M | $6.3M | $5.8M |
| Distributions of earnings received from equity method investments | $0 | $147.0K | $980.0K |
| Income from equity method investments | $0 | -$261.0K | -$485.0K |
| Loss (income) from debt investment | $0 | $1.3M | -$219.0K |
| Loss (gain) on disposal of property and equipment | -$2.2M | -$1.9M | $645.0K |
| Amortization of deferred financing costs | $228.0K | $187.0K | $0 |
| Deferred income tax expense (benefit) | $3.1M | -$3.8M | -$1.4M |
| Accounts receivable, net | $1.2M | -$6.1M | -$1.1M |
| Inventory | $59.0K | $574.0K | -$472.0K |
| Prepaid expenses and other assets | -$503.0K | $544.0K | $2.2M |
| Trade payables | $479.0K | $359.0K | -$859.0K |
| Deferred revenue | $359.0K | $364.0K | $851.0K |
| Accrued liabilities | $255.0K | $2.9M | $5.0M |
| Income tax payable/receivable | -$4.1M | $1.7M | $2.2M |
| Net cash provided by operating activities | $51.9M | $39.1M | $45.2M |
| Purchase of property and equipment | -$40.0M | -$37.8M | -$26.1M |
| Investment in equity investments | $0 | -$1.0M | -$20.0K |
| Cash paid for acquisitions, net of cash acquired | -$26.3M | -$3.0M | -$28.6M |
| Proceeds from sale of debt security | $0 | $750.0K | $0 |
| Proceeds from sale of property and equipment | $16.2M | $10.3M | $2.6M |
| Net cash used in investing activities | -$50.2M | -$30.7M | -$52.1M |
| Proceeds from exercise of options | $1.4M | $1.0M | $1.3M |
| Proceeds from term notes | $9.0M | $0 | $5.0M |
| Principal payments on term notes | -$730.0K | -$1.1M | -$3.7M |
| Proceeds from revolving credit facilities | $13.0M | $3.0M | $8.0M |
| Principal payments on revolving credit facilities | -$13.0M | -$5.0M | -$7.0M |
| Payments for debt issuance costs | -$115.0K | -$192.0K | $0 |
| Shares redeemed to pay income tax | -$1.7M | -$1.1M | -$594.0K |
| Shares repurchased under the share repurchase program | -$13.2M | $0 | $0 |
| Repayments of finance lease liabilities | -$50.0K | -$338.0K | -$157.0K |
| Distributions to non-controlling interest | -$374.0K | -$36.0K | $0 |
| Net cash provided by (used in) financing activities | -$5.8M | -$3.7M | $2.8M |
| Net increase (decrease) in cash and cash equivalents | -$4.0M | $4.7M | -$4.1M |
| Cash paid during the period for interest | $874.0K | $950.0K | $851.0K |
| Cash paid during the period for income taxes, net of refunds | $7.4M | $6.8M | $3.6M |
| Non-cash change in debt from the reclassification of debt issuance costs | $0 | $0 | -$594.0K |
| Net non-cash changes to operating lease | $0 | $0 | -$41.0K |
| Equipment and other fixed asset purchases payable at end of period | $3.2M | $2.2M | $1.4M |
| Equipment sales receivable at end of period | $0 | $2.8M | $0 |
| Non-cash consideration received for sale of debt security | $0 | $125.0K | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
VIEMED HEALTHCARE, INC. sits at the top of its group. 13 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of VIEMED HEALTHCARE, INC.
- Michael Moore Filed SCHEDULE 13D/A on VIEMED HEALTHCARE, INC., latest Sep 24, 2026 (3 filings since May 18, 2023)
- Forager Capital Management, LLC Filed SCHEDULE 13G/A on VIEMED HEALTHCARE, INC., latest Jul 24, 2026 (3 filings since Jul 1, 2025)
- BlackRock Portfolio Management LLC Filed SCHEDULE 13G on VIEMED HEALTHCARE, INC., latest Jul 15, 2025
- THRIVENT FINANCIAL FOR LUTHERANS Filed SCHEDULE 13G/A on VIEMED HEALTHCARE, INC., latest Apr 29, 2025 (6 filings since Feb 14, 2022)
- Nantahala Capital Management, LLC Filed SCHEDULE 13G/A on VIEMED HEALTHCARE, INC., latest Nov 14, 2024 (2 filings since Feb 14, 2024)
- BlackRock Filed SC 13G/A on VIEMED HEALTHCARE, INC., latest Nov 8, 2024 (2 filings since Oct 22, 2024)
- Casey Hoyt Filed SC 13G/A on VIEMED HEALTHCARE, INC., latest Feb 15, 2024 (2 filings since Feb 17, 2022)
- Cove Street Capital, LLC Filed SC 13G/A on VIEMED HEALTHCARE, INC., latest Jun 28, 2022 (2 filings since Mar 14, 2022)
- CI INVESTMENTS INC. Filed SC 13G/A on VIEMED HEALTHCARE, INC., latest Feb 10, 2022
- VIEMED HEALTHCARE, INC. Lafayette, Louisiana
- East Alabama HomeMed, LLC Subsidiary · Alabama, United States
- Home Medical Products, Inc. Subsidiary · Tennessee, United States
- Home Sleep Delivered, L.L.C. Subsidiary · Louisiana, United States
- Lehan Drugs, Inc. Subsidiary · Delaware, United States
- Schofield Homecare Services, Inc. Subsidiary · Alabama, United States
- Sleep Management, L.L.C. Subsidiary · Louisiana, United States
- Spirocare DME, LLC Subsidiary · Tennessee, United States
- Viemed Clinical Services, LLC Subsidiary · Louisiana, United States
- Viemed Healthcare Staffing, LLC Subsidiary · Louisiana, United States
- Viemed Real Estate Holdings, LLC Subsidiary · Louisiana, United States
- Viemed, Inc. Subsidiary · Delaware, United States
- Workforce Delivered, LLC Subsidiary · Louisiana, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What VIEMED HEALTHCARE, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $60.9M5 Dec 31, 2025 | $58.0M5 Dec 31, 2024 | +5.0% |
| Property and equipment, net | $78.8M5 Dec 31, 2025 | $76.3M5 Dec 31, 2024 | +3.3% |
| Finance-lease assets | $05 Dec 31, 2025 | $50.0K5 Dec 31, 2024 | −100.0% |
| Operating-lease assets (leased space) | $3.6M5 Dec 31, 2025 | $2.8M5 Dec 31, 2024 | +26.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $13.5M5 Dec 31, 2025 | $17.5M5 Dec 31, 2024 | −23.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $58.9M5 Dec 31, 2025 | $33.0M5 Dec 31, 2024 | +78.7% |
| Intangible assets, net (excluding goodwill) | $1.3M5 Dec 31, 2025 | $848.0K5 Dec 31, 2024 | +51.5% |
Inventory
Properties, in its own words
We own our headquarters, consisting of approximately 77,000 square feet, located on an approximately 8.2-acre parcel in Lafayette, Louisiana. We also own and occupy a 16,000 square foot office building and a 16,000 square foot climate-controlled warehouse also located in Lafayette, Louisiana. We believe that our facilities are adequate for our needs for the immediate future and that, should it be needed, additional space can be leased on commercially reasonable terms to accommodate any future growth.
Item 2 of the 10-K filed Mar 4, 2026.4
Leadership
Who has led VIEMED HEALTHCARE, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerCasey Hoyt Dec 31, 2020 to now13
- Chief financial officerTrae Fitzgerald Dec 31, 2020 to now14
- Chief operating officerWilliam Todd Zehnder Dec 31, 2020 to now15
Board members and other officers (12)
- Vice President of SalesJerome Cambre Dec 31, 2020 to now16
- Chief Medical OfficerWilliam Frazier Dec 31, 2020 to now17
- Board memberBruce D. Greenstein Dec 31, 2020 to Aug 26, 202418
- Board memberCasey Hoyt Dec 31, 2020 to now13
- Board memberNitin Kaushal Dec 31, 2020 to now19
- Board memberRandy E. Dobbs Dec 31, 2020 to now20
- Board memberSabrina Heltz Dec 31, 2020 to now21
- Board memberTimothy Smokoff Dec 31, 2020 to now22
- Board memberWilliam Frazier Dec 31, 2020 to now17
- Board memberWilliam Todd Zehnder Dec 31, 2020 to now15
- General counselJeremy Trahan Nov 9, 2023 to now23
- General counselEwell Patrick Eagan Dec 31, 2020 to May 11, 202324
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- East Alabama HomeMed, LLC Alabama3
- Home Medical Products, Inc. Tennessee3
- Home Sleep Delivered, L.L.C. Louisiana3
- Lehan Drugs, Inc. Delaware3
- Schofield Homecare Services, Inc. Alabama3
- Sleep Management, L.L.C. Louisiana3
- Spirocare DME, LLC Tennessee3
- Viemed Clinical Services, LLC Louisiana3
- Viemed Healthcare Staffing, LLC Louisiana3
- Viemed Real Estate Holdings, LLC Louisiana3
- Viemed, Inc. Delaware3
- Workforce Delivered, LLC Louisiana3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 20, 20268-K Regulation FD disclosure25
- Aug 3, 20268-K Results of operations26
- Jun 4, 20268-K Executive or director change; Shareholder vote27
- Jun 2, 20268-K Regulation FD disclosure28
- May 5, 20268-K Results of operations29
- Mar 16, 20268-K Regulation FD disclosure30
- Mar 4, 20268-K Results of operations; Regulation FD disclosure; Other events31
- Nov 7, 20258-K Entered a material agreement; Regulation FD disclosure32
- Nov 5, 20258-K Results of operations33
- Sep 23, 20258-K Regulation FD disclosure; Other events34
- Aug 6, 20258-K Results of operations35
- Jul 2, 20258-K Regulation FD disclosure36
- Dec 31, 2020New chief executive Casey Hoyt becomes CEO13
Calendar
Coming up
- Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.09 a share, on Nov 5, 2025.37
When it reported results
- Aug 3, 2026Reported quarterly or annual results26
- May 5, 2026Reported quarterly or annual results29
- Mar 4, 2026Reported quarterly or annual results31
- Nov 5, 2025Reported quarterly or annual results33
- Aug 6, 2025Reported quarterly or annual results35
- May 7, 2025Reported quarterly or annual results38
- Mar 10, 2025Reported quarterly or annual results39
- Nov 6, 2024Reported quarterly or annual results40
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
290 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 161 insider forms, 26 large holders, 23 other. The latest 20:
- Sep 24, 2026SCHEDULE 13D/A EDGAR
- Aug 20, 20268-K EDGAR
- Aug 19, 20264 EDGAR
- Aug 19, 20264 EDGAR
- Aug 19, 20264 EDGAR
- Aug 19, 20264 EDGAR
- Aug 5, 2026S-8 EDGAR
- Aug 3, 202610-Q EDGAR
- Aug 3, 20268-K EDGAR
- Jul 24, 2026SCHEDULE 13G/A EDGAR
- Jun 26, 20264 EDGAR
- Jun 26, 20264 EDGAR
- Jun 4, 20268-K EDGAR
- Jun 2, 20268-K EDGAR
- May 5, 202610-Q EDGAR
- May 5, 20268-K EDGAR
- Apr 22, 2026DEF 14A EDGAR
- Apr 22, 2026DEFA14A EDGAR
- Apr 22, 2026ARS EDGAR
- Mar 20, 2026144 EDGAR
The 290 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
26 open-market trades by officers, directors and large owners since October 2021: 1 buys and 25 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | Frazier WilliamChief Medical Officer | Sale | 10,000 | $11.72 | $117.2K | Form 4 |
| Jun 24, 2026 | Smokoff TimothyDirector | Sale | 20,000 | $11.50 | $230.0K | Form 4 |
| Mar 20, 2026 | Moore MichaelPresident | Sale | 65,000 | $8.77 | $570.0K | Form 4 |
| Mar 19, 2026 | Moore MichaelPresident | Sale | 40,232 | $9.21 | $370.5K | Form 4 |
| Mar 18, 2026 | Moore MichaelPresident | Sale | 31,570 | $9.42 | $297.4K | Form 4 |
| Aug 13, 2025 | Cambre JeromeVice President of Sales | Sale | 4,880 | $7.32 | $35.7K | Form 4 |
| Aug 12, 2025 | Moore MichaelPresident | Sale | 50,090 | $7.33 | $367.2K | Form 4 |
| Jun 30, 2025 | Moore MichaelPresident | Sale | 177,830 | $6.92 | $1.2M | Form 4 |
| Jun 30, 2025 | Kaushal NitinDirector | Sale | 7,048 | $6.91 | $48.7K | Form 4 |
| Jun 27, 2025 | Moore MichaelPresident | Sale | 3,486 | $7.00 | $24.4K | Form 4 |
| Jun 27, 2025 | Kaushal NitinDirector | Sale | 34,100 | $7.01 | $239.0K | Form 4 |
| Jun 26, 2025 | Kaushal NitinDirector | Sale | 8,852 | $7.00 | $62.0K | Form 4 |
| Mar 14, 2025 | Smokoff TimothyDirector | Sale | 3,000 | $7.73 | $23.2K | Form 4 |
| Mar 13, 2025 | Smokoff TimothyDirector | Sale | 8,865 | $7.69 | $68.2K | Form 4 |
| Nov 26, 2024 | Kaushal NitinDirector | Sale | 5,995 | $8.58 | $51.4K | Form 4 |
| Nov 25, 2024 | Kaushal NitinDirector | Sale | 24,005 | $8.70 | $208.8K | Form 4 |
| Nov 20, 2024 | Kaushal NitinDirector | Sale | 15,000 | $8.50 | $127.5K | Form 4 |
| Nov 19, 2024 | Kaushal NitinDirector | Sale | 15,000 | $8.56 | $128.4K | Form 4 |
| Nov 13, 2024 | Dobbs Randy E.Director | Sale | 36,261 | $9.28 | $336.5K | Form 4 |
| Nov 13, 2024 | Kaushal NitinDirector | Sale | 30,000 | $9.48 | $284.4K | Form 4 |
All 26 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Michael MooreSCHEDULE 13D/A, 3 filings May 18, 2023 to Sep 24, 202641
- Forager Capital Management, LLCSCHEDULE 13G/A, 3 filings Jul 1, 2025 to Jul 24, 202642
- BlackRock Portfolio Management LLCSCHEDULE 13G, 1 filing Jul 15, 202543
- THRIVENT FINANCIAL FOR LUTHERANSSCHEDULE 13G/A, 6 filings Feb 14, 2022 to Apr 29, 202544
- Nantahala Capital Management, LLCSCHEDULE 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202445
- BlackRockSC 13G/A, 2 filings Oct 22, 2024 to Nov 8, 202446
- Casey HoytSC 13G/A, 2 filings Feb 17, 2022 to Feb 15, 202447
- Cove Street Capital, LLCSC 13G/A, 2 filings Mar 14, 2022 to Jun 28, 202248
- CI INVESTMENTS INC.SC 13G/A, 1 filing Feb 10, 202249
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | W. Todd Zehnder | $463.2K | $4.1M50 | |
| 2025 | Casey Hoyt | $549.4K | $2.6M50 | |
| 2025 | Michael Moore | $463.2K | $2.0M50 | |
| 2025 | Jeremy Trahan | $296.6K | $987.1K50 | |
| 2025 | Trae Fitzgerald | $271.2K | $914.8K50 | |
| 2024 | Chief Executive Officer and Director | $529.5K | $2.6M50 | |
| 2024 | President | $446.5K | $2.0M50 | |
| 2024 | Chief Operating Officer and Director | $446.5K | $2.0M50 | |
| 2024 | General Counsel | $286.7K | $947.2K50 | |
| 2024 | Chief Financial Officer | $260.7K | $872.2K50 | |
| 2023 | Chief Executive Officer and Director | $509.3K | $2.5M50 | |
| 2023 | President | $429.3K | $2.0M50 | |
| 2023 | Chief Operating Officer and Director | $429.3K | $1.9M50 | |
| 2023 | Chief Financial Officer | $249.4K | $826.4K50 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How VIEMED HEALTHCARE, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARVIEMED HEALTHCARE, INC.1
- CIK0001729149
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inCanada4
- Fiscal year endsDecember 311
- Industry code (SIC)8090 Services-Misc Health & Allied Services, NEC1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address625 E. Kaliste Saloom Rd., Lafayette, LA 705081
- Phone337.504.38021
- Shares outstanding38,088,228 as of Jul 27, 202611
- Public float$238.8M as of Jun 30, 20254
- AuditorErnst & Young LLP, New Orleans, Louisiana PCAOB ID 42; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceFeb 1, 20181
- Filings417 in all: 4 (173), 8-K (91), 10-Q (22), 4/A (19), 3 (13), SC 13G/A (13), 3/A (10), SC 13G (10)1
All 34 form types
10-K (7), DEF 14A (6), DEFA14A (6), S-8 (6), SCHEDULE 13G/A (6), CORRESP (5), 144 (3), ARS (3), UPLOAD (3), EFFECT (2), S-3 (2), SC 13D/A (2), SCHEDULE 13G (2), 10-12B (1), 10-12B/A (1), 10-K/A (1), 8-K/A (1), CERT (1), D (1), DRS (1), DRS/A (1), DRSLTR (1), PRE 14A (1), SC 13D (1), SCHEDULE 13D/A (1), SEC STAFF ACTION (1)
- Latest filingsAnnual report (10-K) Mar 4, 2026
Quarterly report (10-Q) Aug 3, 2026
Proxy statement (DEF 14A) Apr 22, 2026
Latest 8-K (8-K) Aug 20, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Shares, no par value | VMD | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Mar 4, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks VIEMED HEALTHCARE, INC. names in Item 1A of its 10-K filed Mar 4, 2026: 40 risks under these headings, as written.4
- Risks Related to Our Industry and Business
- We compete against companies that have longer operating histories and greater resources, which may result in reduced profit margins and loss of market share.
- Reductions in reimbursement rates may have a materially adverse impact on the profitability of our operations.
- Our reliance on only a few sources of reimbursement for our services could result in delays in reimbursement, which could adversely affect cash flow and revenues.
- A reduction or elimination of coverage or reimbursement of our products by third-party payors, including Medicare, in the future could adversely affect our business and results of operations.
- Our dependence on key suppliers puts us at risk of interruptions in the availability of the equipment we need for our services, which could reduce our revenue and adversely affect our results of operations.
- We conduct all of our operations through our United States subsidiaries and our ability to extract value from these subsidiaries may be limited.
- The failure to attract or to retain management or key operating personnel, including directors, could adversely affect operations.
- We have significant ongoing capital expenditure requirements. If we are unable to obtain necessary capital on favorable terms or at all, we may not be able to execute on our business plans and our business, financial condition, results of operations, cash flows and prospects may be adversely affected.
- We are subject to the risks of litigation and governmental proceedings, which could adversely affect our business.
- Insurance and claims expenses could significantly reduce our profitability.
- We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
The other 29 risks
- The integration of artificial intelligence (AI) technologies may introduce operational risks and challenges.
- Disruptions in the credit and financial markets may have an adverse impact on our ability to obtain capital and financing for our operations.
- Our strategic growth plan, which involves the acquisition of other businesses, may not succeed.
- Adverse global macroeconomic conditions, including supply chain disruptions, tariffs, and fluctuations in foreign currency exchange rates, could negatively impact our operations, costs, and profitability.
- Risks Relating to Government Regulation
- Healthcare reform legislation and/or executive action may affect our business.
- We are subject to extensive federal and state regulation, and if we fail to comply with applicable regulations, we could suffer severe criminal or civil sanctions or be required to make significant changes to our operations that could adversely affect our business, financial condition and operating results.
- We expect the federal and state governments to continue their efforts to contain growth in Medicaid expenditures, which could adversely affect our revenue and profitability.
- Revenue we receive from third-party payors as well as Medicare and Medicaid is subject to potential retroactive reduction.
- As a result of post-payment reviews of claims we submit to Medicare and Medicaid for our services, we may incur additional costs and may be required to repay amounts already paid to us.
- An economic downturn, state budget pressures, sustained unemployment and continued deficit spending by the federal government may result in a reduction in reimbursement and covered services.
- Delays in reimbursement due to claims submission reimbursement processes may cause liquidity problems.
- We depend in part upon reimbursement by third-party payors.
- We face inspections, reviews, audits and investigations under federal and state government programs and contracts. These audits could have adverse findings that may negatively affect our business.
- We are subject to extensive federal and state laws and regulations relating to the privacy and security of protected health information and failure to comply with such laws may increase our operational costs.
- Our products may be subject to future rounds of Medicare's Competitive Bidding Program, which may negatively affect our business and financial condition.
- CMS actions to impose temporary enrollment moratoria and heightened screening for certain DMEPOS supplier types could limit our ability to expand, pursue acquisitions, or maintain expected operational flexibility and could increase our compliance costs.
- If CMS requires prior authorization for our products, our revenue and cash flow could be negatively impacted.
- If we fail to comply with state and federal fraud and abuse laws, including anti-kickback laws, false claims acts, self-referral prohibitions, and anti-inducement laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
- The implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues.
- We are subject to federal, state and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements. Failure to comply with these laws and regulations, or changes to these laws and regulations that increase our employment-related expenses, could adversely impact our operations.
- Risks Related to our Common Shares
- If we fail to establish and maintain proper disclosure controls and procedures or internal control over financial reporting, our ability to produce accurate financial statements and supplemental information, or comply with applicable regulations could be impaired.
- The market price for our common shares may experience substantial volatility for reasons unrelated to our financial performance. This volatility may impact the price at which shareholders can sell their common shares.
- The failure of our common shares to be included in various stock indices could result in the market for our common shares to become limited and volatile and the price at which you can sell your shares to decrease.
- Future sales of our common shares in the public market could reduce our share price, and any additional capital raised by us through the sale of equity or convertible securities may dilute the ownership of existing shareholders.
- We will incur increased costs as a result of operating as a U.S. public reporting company, and our management is required to devote substantial time to new compliance initiatives.
- Because we have no current plans to pay cash dividends on our common shares, investors may not receive any return on their investment unless the value of our common shares appreciates.
- Canadian laws differ from the laws in effect in the United States and may afford less protection to holders of our securities.
- We cannot guarantee that we will repurchase our common shares pursuant to our share repurchase program or that our share repurchase program will enhance long-term shareholder value. Share repurchases could also increase the volatility
- of the price of our common shares and could diminish our cash reserves.
Legal proceedings
From time to time, we may be subject to legal actions and other proceedings, including those that arise in the ordinary course of business, which may include employment matters, breach of contract disputes, as well as governmental and regulatory matters. Please read Note 9 to the Financial Statements, included in Part II, Item 8, of this Annual Report on Form 10-K for more information. Such matters are subject to uncertainties and outcomes that are not predictable with assurance and that may not be known for extended periods of time. In the opinion of management, the outcome of such matters is not expected to have a material adverse effect on our results of operations or financial condition.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARCasey Hoyt, Chief executive officer
- 14
- 15
- 16
- 17
- 18SEC EDGARBruce D. Greenstein, Board member
- 19SEC EDGARNitin Kaushal, Board member
- 20SEC EDGARRandy E. Dobbs, Board member
- 21SEC EDGARSabrina Heltz, Board member
- 22SEC EDGARTimothy Smokoff, Board member
- 23SEC EDGARJeremy Trahan, General counsel
- 24SEC EDGAREwell Patrick Eagan, General counsel
- 25SEC EDGARRegulation FD disclosure
- 26SEC EDGARResults of operations
- 27
- 28SEC EDGARRegulation FD disclosure
- 29SEC EDGARResults of operations
- 30SEC EDGARRegulation FD disclosure
- 31
- 32
- 33SEC EDGARResults of operations
- 34
- 35SEC EDGARResults of operations
- 36SEC EDGARRegulation FD disclosure
- 37NasdaqNasdaq calendar
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50